Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice

Inflammation Research

Volumn 61, Issue 1, 2012, Pages 17-26

  Zhang, Nan N ^a   Huang, Nong Y ^a   Zhou, Xi K ^a   Luo, Xiao L ^a   Liu, Chang Y ^a   Zhang, Yan ^a   Qiu, Ji ^a   Zhang, Yin B ^a   Teng, Xiu ^a   Luo, Can ^a   Chen, Xian C ^a   Kan, Bing ^a   Mao, Yong Q ^a   Tong, Ai P ^a   Wei, Yu Q ^a   Li, Jiong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

BCG LPS; IL 4; Immunological liver injury; Mice

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; GAMMA INTERFERON; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT INTERLEUKIN 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL LIVER INJURY; IMMUNOPATHOLOGY; INFLAMMATORY INFILTRATE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER LEVEL; LIVER NECROSIS; LIVER PROTECTION; METABOLIC INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN DEPLETION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; FEMALE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-4; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; LIVER; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; TEMPERATURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863177675     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0383-9     Document Type: Article

References (48)

1. Liu DF, Wei W, Song LH. Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide: modulation of tumour necrosis factoralpha and interleukin-6 MRNA. Clin Exp Pharmacol Physiol. 2006;33:332-9.
2. Yang YF, Tan DM, Xie YT, Zhao W, Hou ZH, Zhong YD. Mycophenolate mofetil prevents lethal acute liver failure in mice induced by bacille Calmette-Guerin and lipopolysaccharide. J Gastroenterol Hepatol. 2008;23:611-8. (Pubitemid 351501145)
3. Wang H, Wei W, Zhang SY, Shen YX, Yue L, Wang NP, et al. Melatonin-selenium nanoparticles inhibit oxidative stress and protect against hepatic injury induced by Bacillus Calmette- Guerin/lipopolysaccharide in mice. J Pineal Res. 2005;39:156-63. (Pubitemid 41140754)
4. Durez P, Appelboom T, Pira C, Stordeur P, Vray B, Goldman M. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol. 1999;21:581-7. (Pubitemid 29364265)
5. Liu DF, Wei W, Song LH. Upregulation of TNF-alpha and IL-6 mRNA in mouse liver induced by bacille Calmette-Guerin plus lipopolysaccharide. Acta Pharmacol Sin. 2006;27:460-8.
6. Lu JW, Wang H, Yan-Li J, Zhang C, Ning H, Li XY, et al. Differential effects of pyrrolidine dithiocarbamate on TNF-alphamediated liver injury in two different models of fulminant hepatitis. J Hepatol. 2008;48:442-52.
7. Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol. 2004;1:343-50.
8. Kobayashi S, Nishihira J, Watanabe S, Todo S. Prevention of lethal acute hepatic failure by antimacrophage migration inhibitory factor antibody in mice treated with bacille Calmette-Guerin and lipopolysaccharide. Hepatology. 1999;29:1752-9. (Pubitemid 29247049)
9. Guler R, Olleros ML, Vesin D, Parapanov R, Vesin C, Kantengwa S, et al. Inhibition of inducible nitric oxide synthase protects against liver injury induced by mycobacterial infection and endotoxins. J Hepatol. 2004;41:773-81. (Pubitemid 39434307)
10. Sun WY, Wei W, Gui SY, Wu L, Wang H. Protective effect of extract from Paeonia lactiflora and Astragalus membranaceus against liver injury induced by Bacillus Calmette-Guerin and lipopolysaccharide in mice. Basic Clin Pharmacol Toxicol. 2008;103:143-9. (Pubitemid 352019721)
11. Liaw YF, Lee CS, Tsai SL, Liaw BW, Chen TC, Sheen IS, et al. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology. 1995;22: 1368-73.
12. Marinos G, Torre F, Chokshi S, Hussain M, Clarke BE, Rowlands DJ, et al. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology. 1995;22:1040-9.
13. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9:40-6. (Pubitemid 36098258)
14. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst. 1999;91:438-45. (Pubitemid 29128280)
15. Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res. 2007;67:9903-12. (Pubitemid 47621239)
16. Kawakami K, Kawakami M, Husain SR, Puri RK. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. Cancer Res. 2002;62:3575-80. (Pubitemid 34728827)
17. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, et al. Targeted cancer gene therapy using a hypoxia inducible factordependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 2007;67:6872-81. (Pubitemid 47105534)
18. Robert P. Whitehead, Danika Lew, Robert C. Flanigan, Geoffrey R. Weiss, Vivek Roy, Michael L. Glode, Shaker R. Dakhil, E. David Crawford. Phase II trial of recombinant human interleukin- 4 in patients with advanced renal cell carcinoma: a Southwest oncology group study. J Immunother 2002;24:352-358. (Pubitemid 34857290)
19. Gilleece MH, Scarffe JH, Ghosh A, Heyworth CM, Bonnem E, Testa N, Stern P, Dexter TM. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections a phase I dose toxicity trial. Br J Cancer. 1992;66:204-10.
20. Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. British J Haematol. 2000;112:155-160.
21. Ren XX, Li J, Zhou XK, Luo XL, Huang NY, Wang YS, et al. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Dermatology. 2009;219:232-8.
22. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162-72. (Pubitemid 30228378)
23. Yao HW, Yue L. Effect and mechanisms of FR167653, a dual inhibitor of TNF-alpha and IL-1, on BCG plus LPS induced-liver injury. Inflamm Res. 2005;54:471-7. (Pubitemid 41690376)
24. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA. 1992;89:4076-80.
25. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol. 2001;166:2173-7. (Pubitemid 32173445)
26. Brunet LR, Beall M, Dunne DW, Pearce EJ. Nitric oxide and the Th2 response combine to prevent severe hepatic damage during Schistosoma mansoni infection. J Immunol. 1999;163:4976-84. (Pubitemid 29501265)
27. Iribarren P, Cui YH, Le Y, Ying G, Zhang X, Gong W, et al. IL-4 down-regulates lipopolysaccharide-induced formyl peptide receptor 2 in murine microglial cells by inhibiting the activation of mitogen-activated protein kinases. J Immunol. 2003;171:5482-8. (Pubitemid 37432837)
28. Wei S, Wang MWH, Teitelbaum SL, Ross FP. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem. 2002;277:6622-30. (Pubitemid 34968463)
29. Wurfel MM, Monks BG, Ingalls RR, Dedrick RL, Delude R, Zhou D, et al. Targeted deletion of the lipopolysaccharide (LPS)- binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 1997;186:2051-6. (Pubitemid 28013690)
30. Xu DX, Wei W, Sun MF, Wu CY, Wang JP, Wei LZ, et al. Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. Free Radic Biol Med. 2004;37:10-22. (Pubitemid 38746647)
31. Zhihong Lin DZ, Yongqing Yan, Boyang Yu, Qiujuan Wang, Pingniang Shen, Kefeng Ruan. An antioxidant phytotherapy to rescue neuronal oxidative stress. Evidence-based Complement Altern Med 2008; doi:10.1093/ecam/nen053:1-7.
32. Xie P, Sun L, Nayak B, Haruna Y, Liu FY, Kashihara N, Kanwar YS. C/EBP-b modulates transcription of tubulointerstitial nephritis antigen in obstructive uropathy. J Am Soc Nephrol. 2008;4:807-819.
33. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Ann Rev Immunol. 2000;18: 621-63. (Pubitemid 30365393)
34. Kato A, Yoshidome H, Edwards MJ, Lentsch AB. Reduced hepatic ischemia/reperfusion injury by IL-4: potential antiinflammatory role of STAT6. Inflamm Res. 2000;49:275-9. (Pubitemid 30451610)
35. Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, et al. Requirement of IL-4 and liver NK1(?) T cells for concanavalin A-induced hepatic injury in mice. J Immunol. 1997;159:1537-42. (Pubitemid 127484135)
36. Yajima T, Nishimura H, Saito K, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 increases susceptibility to lipopolysaccharide-induced liver injury in mice primed with Mycobacterium bovis bacillus Calmette-Guerin. Infect Immun. 2004;72:3855-62. (Pubitemid 38821898)
37. Song YH, Liu Q, Lv ZP, Chen YY, Zhou YC, Sun XG. Protection of a polysaccharide from Salvia miltiorrhiza, a Chinese medicinal herb, against immunological liver injury in mice. Int J Biol Macromol. 2008;43:170-5.
38. Zou YH, Yang Y, Li J, Li WP, Wu Q. Prevention of hepatic injury by a traditional Chinese formulation, BJ-JN, in mice treated with Bacille-Calmette-Guerin and lipopolysaccharide. J Ethnopharmacol. 2006;107:442-8. (Pubitemid 44344433)
39. Giuliani C, Napolitano G, Bucci I, Montani V, Monaco F. NF-jB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications. Clin Ter. 2001;152:249-53.
40. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol. 2010;53:1059-68.
41. Thomas Michel OF. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997;100:2146-53.
42. Chen F, Kuhn DC, Sun SC, Gaydos LJ, Demers LM. Dependence and reversal of nitric-oxide production on Nf-Kappa-B in Silica and lipopolysaccharide-induced macrophages. Biochem Biophys Res Commun. 1995;214:839-46.
43. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol. 2002;130:25-31.
44. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem. 2003;278:26612-9. (Pubitemid 36876806)
45. Newton RC, Decicco CP. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J Med Chem. 1999;42: 2295-314. (Pubitemid 29305163)
46. Lukkari TA, Jarvelainen HA, Oinonen T, Kettunen E, Lindros KO. Short-term ethanol exposure increases the expression of Kupffer cell CD14 receptor and lipopolysaccharide binding protein in rat liver. Alcohol Alcohol. 1999;34:311-9. (Pubitemid 29295158)
47. Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, Nakanuma Y, et al. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-gammadeficient mice by a concomitant reduction of TNF-alpha, IL-12, and IL-18 production. J Immunol. 1999;162:1049-55. (Pubitemid 29035433)
48. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6- dependent inhibition of NF-kappa B. J Clin Invest. 2001;107: 1375-85. (Pubitemid 32522031)